Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Galcanezumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Post-Traumatic Headache.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2025
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
Details : Galcanezumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Post-Traumatic Headache.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 30, 2025
Details:
Organon expanded its agreement with Eli Lilly to become the sole distributor and promoter of Emgality (galcanezumab), which is indicated for the treatment of migraine.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Organon
Deal Size: Undisclosed Upfront Cash: $22.5 million
Deal Type: Agreement August 20, 2024
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Organon
Deal Size : Undisclosed
Deal Type : Agreement
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Details : Organon expanded its agreement with Eli Lilly to become the sole distributor and promoter of Emgality (galcanezumab), which is indicated for the treatment of migraine.
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : $22.5 million
August 20, 2024
Details:
Under the agreement, Organon becomes the sole distributor and promoter of Emgality (galcanezumab), a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, and RAYVOW™ (lasmiditan), a first-in-class serotonin 5-HT1F receptor agonist, in Europe.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 18, 2023
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Undisclosed
Deal Type : Agreement
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Details : Under the agreement, Organon becomes the sole distributor and promoter of Emgality (galcanezumab), a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, and RAYVOW™ (lasmiditan), a first-in-class serotonin 5-HT1F receptor a...
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 18, 2023
Details:
Emgality (galcanezumab-gnlm) is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraine in adults.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2023
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Emgality (galcanezumab-gnlm) is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraine in adults.
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 16, 2023
Details:
Under the agreement, Affamed will obtain sole commercialization rights upon regulatory approval in Mainland China to Emgality (galcanezumab), a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: AffaMed Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 17, 2023
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : AffaMed Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Affamed Therapeutics To Commercialize Galcanezumab For Migraine Prevention In Mainland China
Details : Under the agreement, Affamed will obtain sole commercialization rights upon regulatory approval in Mainland China to Emgality (galcanezumab), a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 17, 2023
Details:
Galcanezumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2021
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
Details : Galcanezumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 19, 2021
Details:
The study is evaluating once-monthly Emgality® (galcanezumab-gnlm) injection compared to Nurtec® ODT (rimegepant), a tablet patients take every other day, on patient-centric measures, including reductions in monthly migraine headache days and quality of life improvement.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Biohaven Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2021
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Biohaven Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Pati...
Details : The study is evaluating once-monthly Emgality® (galcanezumab-gnlm) injection compared to Nurtec® ODT (rimegepant), a tablet patients take every other day, on patient-centric measures, including reductions in monthly migraine headache days and quality o...
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 18, 2021
Details:
Emgality, a once-monthly injectable monoclonal antibody CGRP antagonist (CGRP mAb), as it compares to Nurtec ODT, a small molecule oral CGRP receptor antagonist (gepant), for the prevention of migraine.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2021
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec®...
Details : Emgality, a once-monthly injectable monoclonal antibody CGRP antagonist (CGRP mAb), as it compares to Nurtec ODT, a small molecule oral CGRP receptor antagonist (gepant), for the prevention of migraine.
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 15, 2021
Details:
A profile comparable to the Emgality device had the highest likelihood of being preferred by nearly half of participants (45.6%) compared to a device profile comparable to Aimovig and AJOVY (29.4% and 25%, respectively).
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2021
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A profile comparable to the Emgality device had the highest likelihood of being preferred by nearly half of participants (45.6%) compared to a device profile comparable to Aimovig and AJOVY (29.4% and 25%, respectively).
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 03, 2021
Details:
Second indication for Emgality, making it the first and only CGRP binding monoclonal antibody approved in Canada to reduce frequency of episodic cluster headache attacks that is also approved for the prevention of migraine in adults who have at least 4 migraine days per month.
Lead Product(s): Galcanezumab,Inapplicable
Therapeutic Area: Neurology Brand Name: Emgality
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2021
Lead Product(s) : Galcanezumab,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Second indication for Emgality, making it the first and only CGRP binding monoclonal antibody approved in Canada to reduce frequency of episodic cluster headache attacks that is also approved for the prevention of migraine in adults who have at least 4 m...
Product Name : Emgality
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Norway
Brand Name : Emgality
Dosage Form : Solution for injection in a pre-filled pen
Dosage Strength : 120 mg
Packaging : Pre-filled pen 1 1ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : USA
Brand Name : EMGALITY
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 120MG/ML
Packaging :
Approval Date :
Application Number : 761063
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : Norway
Brand Name : Emgality
Dosage Form : Solution for injection in a pre-filled pen
Dosage Strength : 120 mg
Packaging : Pre-filled pen 1 1ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Emgality
Dosage Form : Solution For Injection
Dosage Strength : 120mg
Packaging :
Approval Date : 14/11/2018
Application Number : 20171027000060
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Emgality
Dosage Form : Solution For Injection
Dosage Strength : 120mg
Packaging :
Approval Date : 14/11/2018
Application Number : 20171027000077
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Emgality
Dosage Form : Injectable Solution In A Pre-Filled Pen
Dosage Strength : 120mg/ml
Packaging :
Approval Date : 29/03/2019
Application Number : 67026
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Emgality
Dosage Form : Injectable Solution In Pre-Filled Syringe
Dosage Strength : 120MG
Packaging :
Approval Date : 2018-12-19
Application Number : 1181330003
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Emgality
Dosage Form : Injectable Solution In Pre-Filled Pen
Dosage Strength : 120MG
Packaging :
Approval Date : 2018-12-19
Application Number : 1181330001
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : EMGALITY
Dosage Form : SOLUTION
Dosage Strength : 120MG/ML
Packaging :
Approval Date :
Application Number : 2491060
Regulatory Info : Schedule D
Registration Country : Canada
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : EMGALITY
Dosage Form : SOLUTION
Dosage Strength : 120MG/ML
Packaging :
Approval Date :
Application Number : 2491087
Regulatory Info : Schedule D
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
